&w=3840&q=100)
Climate change may fuel spread of fungi that could 'eat you from inside out'
As Covid-19 cases begin to rise again in parts of the world, including India, there's another silent but serious health threat emerging, this time from the fungal kingdom. The rising global temperatures could accelerate the fungi capable of eating you from inside out.
A new climate modelling study by researchers at the University of Manchester shows that rising temperatures could dramatically alter the spread of Aspergillus, a group of airborne fungi known to cause severe respiratory infections in humans and widespread damage to crops.
Published on the preprint platform Research Square, the study titled Climate change-driven geographical shifts in Aspergillus species habitat and the implications forplant and human health maps how the geographical range of three major Aspergillus species could expand significantly by year 2100, exposing millions more people to the risk of infection, especially across Europe and Asia.
Why are Aspergillus fungi a growing concern?
The Aspergillus genus includes several common environmental fungi found in soil, compost, and air. While generally harmless to healthy people, they can cause aspergillosis, a serious respiratory infection, in those with weakened immune systems. These fungi are also notorious for spoiling crops and producing dangerous mycotoxins.
But here's the real problem — they're evolving. Rising global temperatures and widespread use of agricultural fungicides are helping these pathogens become more heat-tolerant and resistant to antifungal drugs, leaving doctors with fewer tools to treat infections.
How rising temperatures increase fungal risks
Using global climate models and species distribution tools, the University of Manchester team simulated how suitable habitats for Aspergillus fungi will shift under three scenarios, including low, intermediate, and high warming.
Impact in a low warming scenario (below 2°C):
Minimal changes in habitat range for Aspergillus species, and the spread is relatively contained.
Impact in intermediate warming (2.5–3°C by 2100):
Noticeable spread of fungal pathogens into new regions, especially in the Northern Hemisphere.
Impact in high warming (around 4°C by 2100):
Significant and rapid expansion of Aspergillus habitats, particularly A. flavus and A. fumigatus, into Europe, North Asia, and North America, putting millions at increased risk.
ALSO READ |
Why scientists are especially alarmed by these findings
Antifungal resistance: A. flavus, in particular, is already resistant to many existing treatments.
Lack of medical tools: There are no vaccines, diagnostics are limited, and antifungal options are few.
Dr Norman van Rhijn, lead author of the study, explains in a statement, 'We've already seen the emergence of Candida auris due to rising temperatures, but this is just the beginning. These maps show how fungal pathogens will likely impact most areas of the world in the future. Raising awareness and developing effective interventions is essential.'
Fungi are shifting toward the Northern Hemisphere
According to the study, the biggest changes will happen in the Northern Hemisphere.
Europe and North Asia: Projected to see the largest increase in fungal suitability due to milder climates becoming warmer.
Africa and South America: Paradoxically, these regions could become too hot for fungi like A. flavus to survive — threatening ecosystems that rely on fungi to decompose organic matter and regulate the carbon cycle.
The study shows a striking poleward shift: fungi are moving north, where millions more people could be exposed.
Climate change threatens food security via fungal spread
The study highlights that A. flavus and A. niger are major crop pathogens, especially for maize, rice, and grapes. The research warns of:
Reduced habitat suitability in current crop-growing zones
Increased risk of contamination in new areas
Food insecurity due to loss and spoilage of yields
Antifungal resistance is also being driven by overuse of fungicides in agriculture, which compromises both plant and human health.
Why fungal threats are difficult to fight
Unlike bacteria, fungi are biologically closer to humans, meaning antifungal drugs often have toxic side effects. Plus, only a tiny fraction of the estimated 1.5 to 3.8 million fungal species have been studied, and less than 10 per cent have been sequenced genetically.
How to prepare for a warming-driven fungal threat
According to the study and public health experts:
Accelerate climate action to limit warming and slow fungal spread
Invest in fungal diagnostics, surveillance, and treatments
Improve awareness among healthcare workers and the public
Develop sustainable farming practices to reduce fungicide-driven resistance
Fungi may not make daily headlines like viruses do, but they are quietly becoming one of the most dangerous climate-driven health threats of our time. As global warming accelerates their spread and evolution, ignoring them is no longer an option. For more health updates, follow #HealthWithBS
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mint
36 minutes ago
- Mint
COVID-19: US FDA approves new lower-dose Moderna-made vaccine — Check details
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target. The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.


Time of India
38 minutes ago
- Time of India
Active Covid cases in India cross 3,000, Kerala leads the surge
India's active Covid-19 cases have crossed the 3,000 threshold, with Kerala reporting the highest number of infections, according to data released by the Union health ministry on Saturday. The number of active cases has risen sharply from 257 on May 22 to 3,395 as of May 31. In the last 24 hours alone, 685 new cases were recorded, and four deaths were reported, one each in Delhi, Kerala, Karnataka and Uttar Pradesh. Health officials maintain there is no reason for alarm. 'The severity of infections is low, with most patients under home care,' an official source told news agency PTI. Dr Rajiv Behl, Director General of the Indian Council of Medical Research (ICMR), said on Monday that genome sequencing from affected regions in the west and south of India confirmed that the variants driving the latest increase are all Omicron subvariants — LF.7, XFG, JN.1, and NB.1.8.1. 'We should monitor and be vigilant, but there is no cause to worry,' he said. The rise in active cases is most pronounced in Kerala (1,336), followed by Maharashtra (467), Delhi (375), Gujarat (265), Karnataka (234), West Bengal (205), Tamil Nadu (185) and Uttar Pradesh (117). Delhi reported the death of a 60-year-old woman who had acute intestinal obstruction, while Karnataka reported a 63-year-old cancer patient who had co-morbidities including tuberculosis. Odisha health secretary Aswathy S urged residents not to panic, assuring that all seven patients in the state are stable and the situation remains under control. 'The latest ICMR report says that the present variant does not exhibit severe symptoms, and most cases are mild,' she said. Delhi chief minister Rekha Gupta has reiterated that the city's hospitals are well-prepared. 'Nineteen patients are hospitalised in Delhi, but there is no need to worry. The government is alert,' she said. An earlier advisory instructed hospitals to ensure the availability of beds, oxygen, antibiotics, and vaccines. Karnataka issues precautionary guidelines As active cases continue to rise in Karnataka, the state's health and family welfare department has issued a detailed advisory aimed at preventing further spread. Healthcare workers have been directed to report all Influenza-Like Illness (ILI) and Severe Acute Respiratory Infections (SARI) cases, especially those with co-morbidities. A portion of these cases will undergo RT-PCR testing, and symptomatic individuals among vulnerable groups — including children, the elderly, and pregnant women, must be tested. The advisory also mandates the tracking of positivity rates and CT values, genome sequencing of severe cases, and sewage surveillance where applicable. With schools set to reopen in June, a separate circular instructed schools to send symptomatic children home and ensure that teachers and staff do not work while ill. 'Avoid crowded or poorly ventilated areas, especially for immunocompromised individuals,' the circular said.


Mint
39 minutes ago
- Mint
COVID-19 cases in India rise to 3,395; Delhi woman among 4 dead in 24 hours, 68 test positive in Maharashtra — 10 points
COVID-19 Cases in India: COVID-19 cases are rising across India, with the country reporting over 3,000 cases and four deaths as of Saturday, May 31. Kerala, Maharashtra, Delhi, Karnataka and West Bengal have the highest number of active cases, according to data from the Union Home Ministry. 1. India now officially has over 3,000 active COVID-19 cases. According to data from the Ministry of Health, the number of active COVID-19 cases in India were 3,395 as of Saturday. The highest number of cases are in Kerala at 1,336, followed by Maharashtra and Delhi. 2. India has reported four Covid-related deaths in the last 24 hours The deceased persons are from Delhi, Kerala, Karnataka and Uttar Pradesh. As per data, 1,435 people have been discharged from hospitals over the past 24 hours. 3. The severity of infections is low, with most of the patients under home care. There is no reason to worry, according to sources quoted by PTI. The situation is being closely monitored, they said. 4. Amid 467 active cases in Maharashtra, the state on Saturday reported 68 new COVID-19 cases. Of the new cases, 30 were detected in Mumbai and 15 from Pune Municipal Corporation limits. Cases were also detected in Kalyan-Dombivali and Raigad. 5. Meanwhile, the Karnataka health department has asked people to stay calm, remain vigilant, and work with health authorities to prevent further spread and ensure public safety. It also issued directions to schools amid the current COVID-19 surge, as they are scheduled to open in June. It has asked government and private schools to take precautions in the interest of school children's health. 6. Delhi has reported one death related to COVID-19 on Saturday. A 60-year-old woman who tested positive for COVID-19 died, marking the first fatality since the recent surge. 'The woman was suffering from acute intestinal obstruction post-laparotomy. The COVID-19 finding was incidental,' an official said. 7. A 63-year-old man with co-morbidities and who tested positive for COVID-19 died at a private hospital in Bengaluru on Saturday. This takes the number of COVID-related deaths in Karnataka to four amid the recent surge. According to the health department statement, the elderly patient who was fully vaccinated was on post operative chemotherapy and had co-morbidities like pulmonary TB with squamous cell carcinoma of buccal mucosa. 8. Since the start of the year, seven COVID-19 patients have died in Karnataka, six of whom had co-morbidities. Adequate coronavirus testing and treatment facilities are available in the state and people should not panic, the health department said. 9. The Karnataka health department has further issued a public advisory, asking people to practice responsible behaviour by wearing masks in crowded places, maintaining physical distancing, and practicing good hygiene. 10. Two more persons tested positive for Covid in Odisha, taking the total number of cases in the state to seven, Health Secretary Aswathy S said on Saturday. Urging people not to panic, she said the condition of all the patients is stable.